RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4.
Authors | |
Abstract | Microsatellite instability high (MSI-H) tumors are malignant tumors that, despite harboring a high mutational burden, often have intact . One of the most frequent mutations in MSI-H tumors is a frameshift mutation in , a ribosomal protein. Here, we identified as a modulator of splicing through an alternative splicing switch in exon 6. loss increases exon 6 inclusion, cell proliferation, and augments resistance to the MDM inhibitor Nutlin-3a. RPL22 represses expression of its paralog, RPL22L1, by mediating the splicing of a cryptic exon corresponding to a truncated transcript. Therefore, damaging mutations in RPL22 drive oncogenic MDM4 induction and reveal a common splicing circuit in MSI-H tumors that may inform therapeutic targeting of the MDM4-p53 axis and oncogenic RPL22L1 induction. |
Year of Publication | 2023
|
Journal | bioRxiv : the preprint server for biology
|
Date Published | 12/2023
|
DOI | 10.1101/2023.12.10.570873
|
PubMed ID | 38106152
|
Links |